Life Sciences team advises AstraZeneca on transaction with Scorpion Therapeutics

2 minute read
24 January 2022

Gowling WLG's life sciences team has advised longstanding client AstraZeneca on its transaction with Scorpion Therapeutics, Inc. ("Scorpion") to develop precision medicines against previously hard-to-target cancer proteins.

Scorpion will focus on discovery and preclinical activities for up to three drug candidates. AstraZeneca would be responsible for development and commercialisation activities worldwide following opt-in, while Scorpion would retain the option to co-develop and co-promote up to two of these programmes in the US under certain conditions, including if AstraZeneca exercises three licence options. Scorpion will receive an upfront cash payment of $75 million together with additional financial terms.

Patrick Duxbury, head of the firm's Life Sciences team in the UK, led the deal, supported by legal director Mathilda Davidson.

Patrick Duxbury said: "This was a great deal to be involved in and one which further supports AstraZeneca's science-led strategy in oncology."

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences